Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.40 |
| ▸ | RELA | Q04206 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318194 | 1.00 | F2 (0.46) | F2F10PRSS1GAACA1 | |
| SCHEMBL10264443 | 0.92 | GAA (0.46) | F2F10PRSS1GAACA1 | |
| SCHEMBL325216 | 0.92 | GAA (0.46) | F2F10PRSS1GAACA1 | |
| SCHEMBL2757112 | 0.86 | MMP1 (0.37) | — | |
| SCHEMBL10792822 | 0.85 | XIAP (0.42) | F2F10PRSS1GAANFKB1 | |
| SCHEMBL10795583 | 0.85 | F2 (0.41) | F2F10PRSS1GAACA1 | |
| SCHEMBL10792831 | 0.85 | XIAP (0.42) | F2F10PRSS1GAANFKB1 | |
| SCHEMBL10795587 | 0.85 | F2 (0.41) | F2F10PRSS1GAACA1 | |
| SCHEMBL10795823 | 0.84 | F2 (0.41) | F2F10PRSS1GAABTK | |
| SCHEMBL10795819 | 0.84 | F2 (0.41) | F2F10PRSS1GAABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330224-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-10-31 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2017075056-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | F2 2894/4885F10 2949/4885PRSS1 1827/4885 |
| US-20190330224-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | F2 2894/4885F10 2949/4885PRSS1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.